Vaccines
1 September 2022
Daiichi Sankyo Announces Initiation of Phase 3 Trial of mRNA COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan31 August 2022
IAVI Announces First Vaccinations at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate27 August 2022
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine19 August 2022
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate13 August 2022
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants3 August 2022
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates26 July 2022
Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox29 June 2022
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV25 June 2022
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA200124 June 2022
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccineNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports